Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-8236 crossover allergen-challenge asthma study
2019-002915-24Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TD-8236 in asthma and airway inflammation (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Area under the curve of change from baseline FEV1 from 3 to 8 hours after inhaled allergen challenge at Day 14. Started Aug 2019; status: completed.
02
Drugs
TD-8236
03
Conditions
asthmaairway inflammation
Beyond the preview
Go deeper on 2019-002915-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002915-24.